NEWS RELEASE

Teijin, Mediridge and TFBS Bioscience to Supply Raw Materials
for Regenerative Medicine Development and Manufacture
Tokyo, Japan, March 28, 2023 --- Teijin Limited, TFBS Bioscience Inc. and Mediridge
Co., Ltd. announced today that they have agreed to supply viral vectors and plasmids
for cell and gene-therapy products that are used to develop and manufacture
regenerative medicines involving gene transfer. Viral vectors, which are viruses thatretain their cell-entry mechanisms but not their original proliferative and toxic functions,
are used to introduce a foreign gene of interest into a cell to express targeted functions.
Plasmids are circular DNA found in bacteria and other microscopic organisms. Since
they replicate independently of chromosomal DNA, they are used as vectors or carriers
that integrate target genes and express genes with targeted functions in cells.
Aiming to contribute to the provision of innovative medical treatments, Teijin, TFBS
Bioscience and Mediridge will collaborate in the design and development of regenerative
medicines, formulation of business plans, and the manufacture investigational drugs andcommercial products including viral vectors. They aim to contribute to the advancementof regenerative medicines by providing customers with one-stop services based onregenerative-medicine platform located in Kashiwanoha Smart City, a life sciencebusiness park near Tokyo. Also, TFBS will expand its business development andcustomer services in Japan through technology development in Kashiwanoha Smart City.
Teijin's contract development and manufacturing organization (CDMO) businessfocused on regenerative medicines includes product design incorporating the know-how
of its group company Japan Tissue Engineering Co., Ltd. (J-TEC) and a one-stop R&Dsystem established with the National Cancer Center Japan and Mitsui Fudosan Co., Ltd.
in Kashiwanoha Smart City. Meanwhile, know-how on gene transfer and viral vector
supply chains are necessary for manufacturing and process development of products forgene cell therapy such as chimeric antigen receptor-T (CAR-T) cell therapy.
TFBS is a biotechnology company that has spun off in October 2016 from theDevelopment Center for Biotechnology, a government-sponsored research institute inTaiwan. TFBS provides CDMO service for viral vectors in compliance with good
manufacturing practice (GMP) requirements. TFBS also provides a one-stop-shop goodlaboratory practice (GLP) testing service to support cell and gene therapy productdevelopment, including assay development, animal safety study, and clinical sample
analysis.
Mediridge is a biotechnology company engaged in studies and consulting related to thedevelopment and manufacturing of gene cell therapy and biopharmaceuticals. Mediridgeowns a facility for manufacturing plasmids and also is the distribution agent for TFBS inJapan.

The alliance will enable Teijin’s regenerative-medicine CDMO business to receive
plasmids from Mediridge and viral vectors from TFBS. Since the number of viral vector
suppliers in Japan is limited, this will allow Teijin to stably provide raw materials toenterprises and academic institutions from initial R&D to commercial production.
Mediridge and TFBS will expand their viral vector business in Japan by receiving
customer referrals from Teijin. In addition, Teijin will provide consultation services incooperation with Mediridge to meet demands for gene transfer and viral vector
development.

TFBS viral vector manufacturing facility
in Taipei, Taiwan

Kashiwanoha Regenerative Medicine
Platform (Mitsui Link Lab Kashiwanoha 1)

About the Teijin GroupTeijin (TSE: 3401) is a technology-driven global group offering advanced solutions in thefields of environmental value; safety, security and disaster mitigation; and demographic
change and increased health consciousness. Originally established as Japan's firstrayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing
three core business domains: high-performance materials including aramid, carbon
fibers and composites, and also resin and plastic processing, films, polyester fibers andproducts converting; healthcare including pharmaceuticals and home healthcare
equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing
care and pre-symptomatic healthcare; and IT including B2B solutions for medical,
corporate and public systems as well as packaged software and B2C online services for
digital entertainment. Deeply committed to its stakeholders, as expressed in the brandstatement “Human Chemistry, Human Solutions”, Teijin aims to be a company that
supports the society of the future. The group comprises some 170 companies andemploys some 20,000 people across 20 countries worldwide. Teijin posted consolidated
sales of JPY 926.1 billion (USD 7.2 billion) and total assets of JPY 1,207.6 billion (USD9.4 billion) in the fiscal year that ended on March 31, 2022.
Press Contact
Investor and Public Relations Department
Teijin Limited
pr@teijin.co.jp

About Mediridge Co., Ltd,
MedRidge is providing one-stop services from research and development (R&D) tobiopharmaceutical manufacturing (GMP) and safety testing (GLP) for researchers andphysicians engaged in biopharmaceuticals, gene therapy, and regenerative medicine,
based on the pillars of conventional basic biotechnology. Since our establishment inFebruary 2009, we have been providing services to pharmaceutical companies anduniversity researchers with management including consulting. In January 2020, welaunched an investigational drug manufacturing facility for plasmid DNA in Uruma City,
Okinawa, which is in increasing need as gene therapy and gene cell therapy progress.
We will continue to provide services based on the concept of "Walking with you primarily
for better medical care and healthier lives. “Contacts+81 3 6661 0041
https://mediridge.com/english

About TFBS Bioscience
TFBS Bioscience Inc. was founded in 2016 as the first Contract Research Organization(CRO) providing biological testing in Taiwan. Our technical team's roots run deeper,
going back to the virus research laboratory founded in 2009 at the Development Centerof Biotechnology (DCB), a government-sponsored research institute in Taiwan. TFBS
has established good reputation and track records in several regulatory submissions,winning trust from the international regulatory agencies and biopharmaceutical industry.
TFBS has launched the first viral vectors Contract Development and Manufacturing
Organization (CDMO) facility in Taiwan, providing fully integrated end-to-end contractdevelopment and manufacturing services for the needs of clinical trials. Nowadays, withour manufacturing expertise and state-of-the-art facility, we are determined to be the best
partner offering clients a one-stop-shop solution for gene and cell therapy. For more
information, please visit www.tfbsbio.com/.
Contacts
https://www.tfbsbio.com
service@tfbsbio.com
Head office: 3F., No.103, Ln. 169, Kangning St., Xizhi District
New Taipei City Taiwan (R.O.C)
Tel: 886-2-26947888